

# **A Pilot Study of Dual Anti-Hypertensive Medication Management with Novel Lab Monitoring in Rural Western Uganda: An Initiative of the Bugoye Hypertension Improvement Project (B-HIP)**

Oludamilola (Dami) Aladesanmi, IM PGY-3

OGHE Global Health Forum – Global Health Scholars Program

January 23, 2023



**SCHOOL OF  
MEDICINE**



# Overview

- Objectives
- Background
- Methods
- Preliminary Results
- Discussion

# Objectives

- Define and discuss hypertension (HTN), its risks, and its global and regional burden
- Consider sub-Saharan Africa (SSA) and projected changes in population, demographics, and burden of disease
- Discuss HTN treatment
- Present the Bugoye Hypertension Improvement Project (B-HIP)
- Describe HTN treatment and the addition of novel lab monitoring in Bugoye, Uganda
- Reflect on this process and its ramifications for HTN and non-communicable disease (NCD) management in similar settings



SCHOOL OF  
MEDICINE

# Background


# The Story of Joseph



# HTN and Cardiovascular Disease (CVD)

## Relationship between SBP and Risk of Ischemic Heart Disease and Stroke Mortality

One Million Adults, 61 Prospective Studies



Lewington S, et al. *Lancet*. 2002;360:1903-1913.

As SBP/DBP increases 20/10, 2x risk of CVD and stroke death




# Hypertension (HTN)

- Previously: JNC8 guidelines (2014):
  - SBP > 140 or DBP > 90\*
  - Treatment guidelines:
    - If age < 60, start meds for goal BP < 140/90
    - If age > 60, start meds for goal BP < 150/90

- Latest update: ISH guidelines (2020):

**Blood Pressure Categories**




BLOOD PRESSURE CATEGORY	SYSTOLIC mm Hg (upper number)		DIASTOLIC mm Hg (lower number)
<b>NORMAL</b>	<b>LESS THAN 120</b>	<b>and</b>	<b>LESS THAN 80</b>
<b>ELEVATED</b>	<b>120 – 129</b>	<b>and</b>	<b>LESS THAN 80</b>
<b>HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 1</b>	<b>130 – 139</b>	<b>or</b>	<b>80 – 89</b>
<b>HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 2</b>	<b>140 OR HIGHER</b>	<b>or</b>	<b>90 OR HIGHER</b>
<b>HYPERTENSIVE CRISIS (consult your doctor immediately)</b>	<b>HIGHER THAN 180</b>	<b>and/or</b>	<b>HIGHER THAN 120</b>

\*SBP = systolic blood pressure; DBP = diastolic blood pressure

# Burden of HTN: Globally & in Sub-Saharan Africa (SSA)

- Leading cause of preventable deaths globally
- Affects 1.39 billion people
  - >80% of this global burden is in LMICs
- SSA: 10-20 million out of 650 million
  - As high as 38% among some communities
  - Data limitations
- 2015 cross-sectional study sampling Uganda, South Africa, Tanzania, and Nigeria
  - Increased with age, BMI
  - Increased with urban (vs rural)
  - Pre-HTN rates: 21% - still at risk






# SSA: Population Projections

- Expansive population growth projected in SSA:
  - 2000-2050: 800 million to 2.4 billion
  - 2050-2100: 2.4 billion to 4.2 billion
- By 2100:
  - Population of SSA  $\approx$  Asia
  - Nearly 2 out of every 5 people will be African

## Population growth in Africa is projected to remain strong throughout this century

Population by region, in billions



Note: Data labels show projected peak population for each region: Europe (2021), Asia (2055) and Latin America and the Caribbean (2058). Regions follow United Nations definitions and may differ from other Pew Research Center reports.

Source: United Nations Department of Economic and Social Affairs, Population Division, "World Population Prospects 2019."

PEW RESEARCH CENTER

# Treatment of HTN

- 1<sup>st</sup> line: lifestyle interventions
  - Weight loss
  - Dietary modifications (Dietary Approaches to Stop HTN [DASH], Mediterranean)
  - Sodium reduction
  - Increased potassium
  - Physical activity



- 1<sup>st</sup> line medications:
  - Dihydropyridine (DHP) calcium channel blockers (e.g. **amlodipine, -pine**, etc.)
  - Renin-angiotensin II-aldosterone system (RAAS) inhibitors:
    - Angiotensin-converting enzyme (ACE) inhibitor: **lisinopril, -pril**, etc.
    - Angiotensin II receptor blocker (ARB): **valsartan, -sartan**, etc.
  - Thiazide diuretics: **chlorthalidone, hydrochlorothiazide (HCTZ), -thiazide**, etc.
- 2<sup>nd</sup> line medications: many
  - Beta-blockers (**carvedilol, metoprolol, -lol**, etc.)
  - Mineralocorticoid receptor antagonists (MRAs) – aka **spironolactone, -one**, etc.
  - Alpha-blockers (doxazosin, prazosin, **-osin**, etc.)
- Notes:
  - Best evidence: combo therapy with first-line medications
  - Multiple mechanisms




# Treatment Strategies in Rural Contexts

- “Cascade of care” in rural Uganda (Kotwani et al.)
  1. Community or health center screening → HTN diagnosis
  2. Establishing care
  3. Management, starting medications
  4. Patient retention
  5. HTN control
- Leverages successful HIV care delivery systems

# The Bugoye Hypertension Improvement Program (B-HIP)

- Established 2014 within the Bugoye Health Center due to local HTN morbidity & mortality
- Bugoye Health Center (BHC):
  - Kasese District of western Uganda
  - Referral center for the Bugoye sub-county
  - Serves rural population, ~50K
    - Most transit by foot; ~45 minutes one-way
  - Level III health center:
    - Has outpatient clinic, maternity ward, and lab testing
    - No guaranteed federal support



**Figure 1:** Map of the Bugoye sub-county showing the location of health facilities.

# Establishing BHIP

- Weekly HTN clinic with community health workers (CHW) and research assistants
- Before opening, trained clinic workers on emphasizing lifestyle modifications with teaching on medication mgmt.
- Local thiazide diuretic (Bendroflumethiazide, aka BFT) on formulary
  - However, inconsistent availability locally
- Later, grant from Pfizer & Direct Relief procured amlodipine for many patients
- Over 600 patients currently enrolled



- Some research suggests specific combo of amlodipine & thiazide diuretic is optimal in SSA population (Ojji et al., CREOLE Study)
- Though thiazides (& other anti-HTN medications) can cause electrolyte abnormalities and renal changes, regular lab monitoring is not standard of care in resource-limited contexts (WHO, Ugandan Ministry of Health)
- **We present a subset of HTN patients on maximum amlodipine therapy, hypothesizing combination with thiazide diuretics are associated with better BP control with minimal adverse effects and low cost**
- **We introduce electrolyte and renal function measurement (Na, K, Cr) to optimally describe our patients and introduce novel monitoring of adverse medication effects**



UNC

SCHOOL OF  
MEDICINE

# Methods



# Study Protocol: Recruitment and Population

- Clinic patients (non-pregnant adults) with SBP  $\geq$  140 and/or DBP  $\geq$  90 who are already on amlodipine 10mg daily (maximum dose) but not currently on BFT
  - Recruited over 6 months from either previously established patients with highest BP (most clinical benefit) or new patients with HTN on amlodipine 10mg
- Presented to clinic with blood pressure checked (per clinic protocol) and prescribed BFT 5mg daily
- Follow up appointment in 2 weeks for phlebotomy-drawn sodium (Na), potassium (K), and creatinine (Cr) and rechecked blood pressure
- All data recorded in shared RedCap
- Meetings between US-based team and Uganda-based team conducted approximately weekly for updates and troubleshooting

# Methodological Challenges

- A few weeks into study, lab results notable for higher-than-expected rates of hypernatremia and hyperkalemia
  - Thiazide diuretics should be associated with low Na and low K
- Team coordinated meeting with contracted lab manager to inquire about quality control mechanisms
- Due to our concerns, we tested a limited sample of study patients at a secondary lab facility
  - More plausible results at 2ndary location, and different from 1<sup>st</sup> lab's results
- Ultimate decision made to terminate old contract and start new contract with secondary lab
  - Attempted to contact patients with erroneous labs for repeat draw



UNC

SCHOOL OF  
MEDICINE

# Preliminary Results

# Enrollment Challenges

- Planned for 80 study participants, but 92 patients were seen for blood pressure checks (due to lab quality setback)
  - 76 patients ultimately had accurate labs
  - About 43 patients lost-to-follow-up
    - New patients; patients who did not return as scheduled for follow-up

# Baseline Characteristics

Characteristics (N=92)	Mean
Years of follow-up (minimum, maximum)	0.5 (0,6)
Gender (Female)	64 (70%)
Age, yrs median (IQR)	60 (IQR 51-66)
HIV positive	0
Any smoking?	0
BMI	24.7 (SD 4.90)

Method of Transportation to Clinic	
Foot	40
Boda boda (motorcycle)	49
Other (car or bicycle)	1
Transit Time to Clinic (minutes, mean)	2
Occupation	
Farmer	79
Business	6
Civil Servant	5
Other	2

# Blood Pressure Changes

Category (N=49)	Results
Baseline Mean SBP	154
Follow-up Mean SBP	141
Difference	13 mmHg

Category (N=49)	Results
Baseline Mean DBP	93
Follow-up Mean DBP	84
Difference	9 mmHg

# Adverse Effects, Lab Studies (& Future Analysis)

Adverse Effects	n
Hyponatremia (Na < 130)	1
Hypokalemia (K < 3)	0
Elevated creatinine	2
Dizziness	0

Labs	Mean	SD
Sodium (Na)	142	4.2
Potassium (K)	4.3	0.4
Creatinine (Cr)	0.68	0.27

- Still to come:
  - Overall proportion of BP control in cohort
  - Measures of association for various demographics in our study (e.g. gender, mode of transport, occupation, etc.)
  - Additional descriptive analysis



UNC

SCHOOL OF  
MEDICINE

# Discussion



# Study Results

- Our addition of BFT 5mg to amlodipine 10mg daily was associated with a clinically significant reduction in both SBP (13mmHg) and DBP (9mmHg)
- However, results limited by loss-to-follow-up
- Very few patients in our sample had labs concerning for renal dysfunction, and only one had sodium abnormalities
  - However, notable on individual level – this person had Na of 118
  - Unable to reach after appointment to assess symptoms
  - Returned after 3 months, sodium had normalized on repeat check

# NCD Management in Rural Uganda (and Beyond?)

- Model proposed by Kotwani et al. provides helpful framework for HTN management in this context
  - Linkage to care progresses from screening all the way to management and control
  - Our study supports the utility of this model
  - Could this be expanded to other NCDs? Other LMICs?
    - Future BHIP goals: diabetes management, aspirin for primary prevention of ASCVD
- Any worthwhile global health project should be scalable
  - Hope to work on this with another new HTN clinic during upcoming trip to Uganda in March

# Limitations

- High loss-to-follow-up in the study
  - Adherence rates are high in the clinic overall
  - Good referral base
- Small sample size, so low power
  - We present a pilot study which demonstrates ability to scale
- Difficult to adjudicate adherence (self-reported)
  - However, decreased adherence would indicate under-estimating results
- Initial confounder of reliable lab monitoring
  - Requires community-based partnerships for effective patient care and research

# Conclusions

- Combination therapy with amlodipine and thiazide diuretic associated with decreased BP and improved BP control in this rural western Ugandan cohort
- Consistent follow-up remains challenging in this remote region
- Benefits of lab monitoring in this context remain debatable
- Cost-effective:
  - 1 pack (100 tablets) of BFT = 4618.28 UGX  $\approx$  \$1.22 USD
    - Therefore, one-year supply of BFT for one patient: <\$4.50
- Opportunities for HTN “cascade of care” guiding other NCD management

# References

- *Africa's MICs*. World Bank Blogs. (n.d.). Retrieved January 16, 2023, from <https://blogs.worldbank.org/africacan/africas-mics>
- Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Estep K, Hassen Abate K, Akinyemiju TF, Ali R, Alvis-Guzman N, Azzopardi P, Banerjee A, Barnighausen T, Basu A, Bekele T, Bennett DA, Biadgilign S, Catalá-López F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R, Hankey GJ, Jonas JB, Judd SE, Khang YH, Khosravi A, Kim YJ, Kimokoti RW, Kokubo Y, Kolte D, Lopez A, Lotufo PA, Malekzadeh R, Melaku YA, Mensah GA, Misganaw A, Mokdad AH, Moran AE, Nawaz H, Neal B, Ngalesoni FN, Ohkubo T, Pourmalek F, Rafay A, Rai RK, Rojas-Rueda D, Sampson UK, Santos IS, Sawhney M, Schutte AE, Sepanlou SG, Shifa GT, Shiue I, Tedla BA, Thrift AG, Tonelli M, Truelsen T, Tsilimparis N, Ukwaja KN, Uthman OA, Vasankari T, Venketasubramanian N, Vlassov VV, Vos T, Westerman R, Yan LL, Yano Y, Yonemoto N, Zaki ME, Murray CJ. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. *JAMA*. 2017 Jan 10;317(2):165-182. doi: 10.1001/jama.2016.19043. Erratum in: *JAMA*. 2017 Feb 14;317(6):648. PMID: 28097354.
- Ferdinand, K., Reddy, T. & Vo, T. (2021). Global interventions in hypertension: new and emerging concepts. *Current Opinion in Cardiology*, 36 (4), 436-443. doi: 10.1097/HCO.0000000000000866.
- Guwatudde, D., Nankya-Mutyoba, J., Kalyesubula, R. *et al.* The burden of hypertension in sub-Saharan Africa: a four-country cross sectional study. *BMC Public Health* 15, 1211 (2015). <https://doi.org/10.1186/s12889-015-2546-z>
- *Evaluating linkage to care for hypertension after community-based screening in rural Uganda—Kotwani—2014—Tropical Medicine & International Health—Wiley Online Library*. (n.d.). Retrieved January 19, 2023, from <https://onlinelibrary.wiley.com/doi/full/10.1111/tmi.12273>
- Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360:1903–13.
- Millman, N., White, J. B., Sitrin, S. S. and C., & Gerstein, B. M. and J. (2015, May 5). *The African Century*. POLITICO Magazine. Retrieved January 15, 2023, from <https://www.politico.com/magazine/story/2015/05/africa-will-dominate-the-next-century-117611/>
- minqi7. (2017, July 8). *Bugoye Health Center*. INDY-pendent. Retrieved January 22, 2023, from <https://minqi7.wordpress.com/2015/05/10/bugoye-health-center/>
- *New ACC/AHA high blood pressure guidelines lower definition of hypertension*. American College of Cardiology. (2017, November 13). Retrieved January 15, 2023, from <https://www.acc.org/latest-in-cardiology/articles/2017/11/08/11/47/mon-5pm-bp-guideline-aha-2017>
- Ojji, D. B., Mayosi, B., Francis, V., Badri, M., Cornelius, V., Smythe, W., Kramer, N., Barasa, F., Damasceno, A., Dzudie, A., Jones, E., Mondo, C., Ogah, O., Ogola, E., Sani, M. U., Shedul, G. L., Shedul, G., Rayner, B., Okpechi, I. G., ... CREOLE Study Investigators. (2019). Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. *The New England Journal of Medicine*, 380(25), 2429–2439. <https://doi.org/10.1056/NEJMoa1901113>
- Pew Research Center. (2019, June 17). *Population growth in Africa is projected to remain strong throughout this century*. Pew Research Center. Retrieved January 15, 2023, from [https://www.pewresearch.org/fact-tank/2019/06/17/worlds-population-is-projected-to-nearly-stop-growing-by-the-end-of-the-century/ft\\_19-06-17\\_worldpopulation\\_population-growth-africa-projected-remain-strong/](https://www.pewresearch.org/fact-tank/2019/06/17/worlds-population-is-projected-to-nearly-stop-growing-by-the-end-of-the-century/ft_19-06-17_worldpopulation_population-growth-africa-projected-remain-strong/)

# Acknowledgements

- Office of Global Health Education (OGHE)
- UNC Internal Medicine Residency Program
- The entire P-HEALED team (including but not limited to):
  - Dr. Raquel Reyes
  - Dr. Anthony Muiro, Dr. Samson Okello
  - Susan Babirye
  - Wilfred (Willy) Isegutiya
  - Clovis Baluku, Emmanuel (Emma) Baguma, Emmanuel (Emma) Ayebare
  - & many more!
- My family (for their overwhelming support – and patience)

Consider supporting the  
work of P-HEALED:

**THANK YOU!**

